A Wang1, H Y Wang2, Y Liu3, M C Zhao1, H J Zhang4, Z Y Lu1, Y C Fang1, X F Chen5, G T Liu6. 1. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai, China. 2. Central Laboratory, Shanghai Pulmonary Hospital, Shanghai, China. 3. Department of Radiotherapy, Shanghai Pulmonary Hospital, Shanghai, China. 4. Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University School of Medicine, Shanghai, China. 5. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai, China; Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University School of Medicine, Shanghai, China. Electronic address: Dr_chenxiaofeng@126.com. 6. Center for Translational Medicine, Shanghai Pulmonary Hospital, Shanghai, China. Electronic address: liugt@tongji.edu.cn.
Abstract
BACKGROUND: A meta-analysis was conducted to investigate the much-debated relationship between the gene expression of programmed cell death-ligand 1 (PD-L1) and cancer patient prognosis. The prognostic value of measuring PD-L1 expression in non-small cell lung cancer (NSCLC) patients was analyzed. METHODS: We searched PubMed for studies about the relationship between PD-L1 expression and NSCLC patient prognosis. Only studies with patient survival data related to PD-L1 expression in NSCLC patients with different characteristics were included. The effect size (ES) for this analysis was the hazard ratio (HR) with 95% confidence intervals (CI) for overall survival (OS). RESULTS: Six studies with 1157 patients were included with the defined including and excluding criteria. There is no significant heterogeneity among the studies (I(2) = 0%, p = 0.683). PD-L1 expression was significantly associated with the differentiation of tumor (poor vs. well: OR = 1.91, 95% CI: 1.33-2.75, p = 0.001). High PD-L1 expression was also correlated with poor prognosis in terms of the OS of patients with NSCLC (pooled HR = 1.75, 95% CI: 140-2.20, p < 0.001; heterogeneity test: I(2) = 0%, p = 0.643). CONCLUSIONS: NSCLC patients with positive PD-L1 expression exhibited poor OS. The PD-L1 expression was higher in tumors with poor differentiation.
BACKGROUND: A meta-analysis was conducted to investigate the much-debated relationship between the gene expression of programmed cell death-ligand 1 (PD-L1) and cancerpatient prognosis. The prognostic value of measuring PD-L1 expression in non-small cell lung cancer (NSCLC) patients was analyzed. METHODS: We searched PubMed for studies about the relationship between PD-L1 expression and NSCLCpatient prognosis. Only studies with patient survival data related to PD-L1 expression in NSCLCpatients with different characteristics were included. The effect size (ES) for this analysis was the hazard ratio (HR) with 95% confidence intervals (CI) for overall survival (OS). RESULTS: Six studies with 1157 patients were included with the defined including and excluding criteria. There is no significant heterogeneity among the studies (I(2) = 0%, p = 0.683). PD-L1 expression was significantly associated with the differentiation of tumor (poor vs. well: OR = 1.91, 95% CI: 1.33-2.75, p = 0.001). High PD-L1 expression was also correlated with poor prognosis in terms of the OS of patients with NSCLC (pooled HR = 1.75, 95% CI: 140-2.20, p < 0.001; heterogeneity test: I(2) = 0%, p = 0.643). CONCLUSIONS:NSCLCpatients with positive PD-L1 expression exhibited poor OS. The PD-L1 expression was higher in tumors with poor differentiation.
Authors: Emily B Ehlerding; Hye Jin Lee; Todd E Barnhart; Dawei Jiang; Lei Kang; Douglas G McNeel; Jonathan W Engle; Weibo Cai Journal: Bioconjug Chem Date: 2019-04-19 Impact factor: 4.774